Insider · CIK 0001615840

O'Loughlin Steve

Reports to the SEC for 3 companies · HOUSTON, TX

sec.gov

Transactions

Companies

Filings

CIK

0001615840

Forms 4 and 5

Insider transactions

22 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-03-02	CNSPCNS Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+9,500 sh	—	—	9,500
2025-03-31	ATNMActinium Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−3,333 sh	—	—	0
2025-03-31	ATNMActinium Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−1,666 sh	—	—	0
2025-03-31	ATNMActinium Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−3,333 sh	—	—	0
2025-03-31	ATNMActinium Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−8,833 sh	—	—	0
2025-03-31	ATNMActinium Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−13.3K sh	—	—	0
2025-03-31	ATNMActinium Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−59.1K sh	—	—	0
2025-03-31	ATNMActinium Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−107K sh	—	—	0
2025-03-31	ATNMActinium Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−256K sh	—	—	0
2025-03-31	ATNMActinium Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−253K sh	—	—	0
2023-12-28	ATNMActinium Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+253K sh	—	—	253,123
2022-07-01	ATNMActinium Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+256K sh	—	—	256,348
2021-09-01	ATNMActinium Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+107K sh	—	—	107,463
2020-08-12	ATNMActinium Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+59.1K sh	—	—	59,066
2019-07-12	ATNMActinium Pharmaceuticals, Inc. · Options to purchase common stockA Award	Chief Financial Officer	AAward	+400K sh	$0.23	+$92.8K	400,000
2018-12-10	ATNMActinium Pharmaceuticals, Inc.P Purchase	Chief Financial Officer	PPurchase	+10K sh	$0.43	+$4,350	35,500
2018-07-13	ATNMActinium Pharmaceuticals, Inc. · Options to purchase common stockA Award	Chief Financial Officer	AAward	+265K sh	$0.78	+$207K	265,000
2018-06-15	ATNMActinium Pharmaceuticals, Inc.P Purchase	Chief Financial Officer	PPurchase	+12K sh	$0.50	+$6,000	25,500
2018-03-06	ATNMActinium Pharmaceuticals, Inc.J Other	Chief Financial Officer	JOther	+10K sh	$0.50	+$5,000	13,500
2018-03-06	ATNMActinium Pharmaceuticals, Inc. · Series A WarrantsJ Other	Chief Financial Officer	JOther	+2,500 sh	$0.50	+$1,250	2,500
2018-03-06	ATNMActinium Pharmaceuticals, Inc. · Series B WarrantsJ Other	Chief Financial Officer	JOther	+7,500 sh	$0.50	+$3,750	7,500
2017-06-15	ATNMActinium Pharmaceuticals, Inc.P Purchase	Chief Financial Officer	PPurchase	+3,500 sh	$1.17	+$4,095	3,500

Recent filings

Accepted (ET)
Mar 44
O'Loughlin Steve0001683168-26-001489
SEC(opens sec.gov)
Apr 24
O'Loughlin Steve0001213900-25-028225
SEC(opens sec.gov)
Dec 294
O'Loughlin Steve0001213900-23-100077
SEC(opens sec.gov)
Jul 14
O'Loughlin Steve0001213900-22-036877
SEC(opens sec.gov)
Sep 34
O'Loughlin Steve0001213900-21-046684
SEC(opens sec.gov)
Aug 144
O'Loughlin Steve0001213900-20-022342
SEC(opens sec.gov)
Jul 164
O'Loughlin Steve0001213900-19-012881
SEC(opens sec.gov)
Dec 104
O'Loughlin Steve0001213900-18-017143
SEC(opens sec.gov)
Jul 174
O'Loughlin Steve0001213900-18-009315
SEC(opens sec.gov)
Jun 154
O'Loughlin Steve0001213900-18-007754
SEC(opens sec.gov)
Mar 84
O'Loughlin Steve0001213900-18-002726
SEC(opens sec.gov)

Companies

Address

C/O CNS PHARMACEUTICALS, INC. 100 WEST LOOP SOUTH, SUITE 900

HOUSTON, TX, 77027